Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2020

Nov 16, 2020

SELL
$22.99 - $36.34 $4.68 Million - $7.4 Million
-203,500 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$29.88 - $56.74 $2.99 Million - $5.67 Million
100,000 Added 96.62%
203,500 $6.83 Million
Q1 2020

May 15, 2020

BUY
$33.0 - $54.5 $3.42 Million - $5.64 Million
103,500 New
103,500 $4.17 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.27B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Great Point Partners LLC Portfolio

Follow Great Point Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Point Partners LLC with notifications on news.